Brokerages Set NewAmsterdam Pharma (NASDAQ:NAMS) PT at $36.20

NewAmsterdam Pharma (NASDAQ:NAMS) has been given a consensus rating of “Buy” by the six analysts that are presently covering the stock, MarketBeat reports. Six research analysts have rated the stock with a buy rating. The average 1 year price target among analysts that have issued a report on the stock in the last year is $36.20.

A number of brokerages have recently weighed in on NAMS. Needham & Company LLC restated a “buy” rating and issued a $36.00 target price on shares of NewAmsterdam Pharma in a research note on Thursday, December 5th. Scotiabank raised their price objective on shares of NewAmsterdam Pharma from $35.00 to $47.00 and gave the company a “sector outperform” rating in a research report on Wednesday, December 11th. Piper Sandler reiterated an “overweight” rating and set a $37.00 target price on shares of NewAmsterdam Pharma in a research report on Monday, September 23rd. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $31.00 price target on shares of NewAmsterdam Pharma in a report on Thursday, September 5th.

Insider Buying and Selling at NewAmsterdam Pharma

In related news, CAO Louise Frederika Kooij sold 45,000 shares of the stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $15.72, for a total value of $707,400.00. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, major shareholder Nap B.V. Forgrowth sold 25,132 shares of the business’s stock in a transaction that occurred on Monday, December 23rd. The shares were sold at an average price of $25.49, for a total transaction of $640,614.68. Following the transaction, the insider now owns 10,777,092 shares of the company’s stock, valued at approximately $274,708,075.08. This represents a 0.23 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 428,446 shares of company stock valued at $10,514,105. 19.50% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Banque Cantonale Vaudoise acquired a new position in NewAmsterdam Pharma in the 2nd quarter worth $38,000. Quarry LP raised its position in NewAmsterdam Pharma by 2,469.2% in the 3rd quarter. Quarry LP now owns 6,500 shares of the company’s stock valued at $108,000 after buying an additional 6,247 shares during the last quarter. Barclays PLC lifted its stake in NewAmsterdam Pharma by 1,813.4% in the 3rd quarter. Barclays PLC now owns 7,596 shares of the company’s stock valued at $126,000 after acquiring an additional 7,199 shares in the last quarter. Bellevue Group AG acquired a new position in NewAmsterdam Pharma during the 3rd quarter worth approximately $128,000. Finally, XTX Topco Ltd bought a new position in shares of NewAmsterdam Pharma during the 3rd quarter worth approximately $187,000. Institutional investors and hedge funds own 89.89% of the company’s stock.

NewAmsterdam Pharma Stock Performance

NASDAQ NAMS opened at $25.86 on Thursday. The stock’s 50-day moving average is $21.99 and its two-hundred day moving average is $19.17. NewAmsterdam Pharma has a fifty-two week low of $10.50 and a fifty-two week high of $27.29.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.